مباشر
Endpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026Lonza NewsAmMax Bio licenses ADC technology from Lonza - The Pharma LetterFDA News ReleasesFDA Expands Sunscreen Options for the First Time in 20 YearsEndpoints NewsPharma and biotech salaries: Top-paying companies of 2025FierceBiotechRoche sticks with €600M diagnostics investment in Germany but warns of future risk10x Genomics Blog10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocusFierceBiotechCeQur nabs $100M series E to fuel insulin patch commercialization
eLife ٢٣ يناير ٢٠٢٦

Robust assessment of asymmetric division in colon cancer cells

Robust assessment of asymmetric division in colon cancer cells

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.